The GLP is committed to full transparency. Download and review our Annual Report.

The GLP is committed to full transparency. Download and review our Annual Report.

Talking Biotech: Thalidomide once caused birth defects—now it treats cancer

The drug thalidomide was developed with tremendous promise in managing a variety of disorders, such as anxiety and morning sickness. However, a few years after its common use, it became linked to a suite of birth defects, primarily defects in limb development. For almost sixty years scientists have tried to unravel the molecular basis of its action.

Dr. Katherine Donovan, a postdoctoral researcher at the Dana Farber Cancer Institute at Harvard University, was the primary author on recent work that describes the molecular basis of thalidomide-based disorders. Ironically, understanding its roles in developmental disorders also illuminates possible roles in disease treatment, as it is used in treatment of some cancers and may find wider application in the future.

Related article:  Eating organic food reduces risk of some cancers, controversial study claims

Dr. Katherine Donovan’s website
Follow her on Twitter @kdonovan1008

Like the podcast? Please subscribe and write a review! Stitcher iTunes Player FM Pod Directory TuneIn

Visit the Talking Biotech website

Follow Talking Biotech on Twitter @TalkingBiotech

Follow Kevin Folta on Twitter @kevinfolta | Facebook: Facebook.com/kmfolta/ | Lab website: Arabidopsisthaliana.com | All funding: Kevinfolta.com/transparency

Follow Paul Vincelli on Twitter @Pvincell | University of Kentucky webpage 

News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend